DexCom, Inc. (NASDAQ:DXCM) Shares Bought by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company raised its holdings in shares of DexCom, Inc. (NASDAQ:DXCMFree Report) by 0.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 314,573 shares of the medical device company’s stock after acquiring an additional 1,363 shares during the period. The Manufacturers Life Insurance Company owned approximately 0.08% of DexCom worth $39,035,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the business. Norges Bank acquired a new stake in DexCom during the fourth quarter worth about $540,178,000. Artisan Partners Limited Partnership increased its holdings in shares of DexCom by 164.8% during the 4th quarter. Artisan Partners Limited Partnership now owns 5,900,308 shares of the medical device company’s stock valued at $732,169,000 after purchasing an additional 3,672,471 shares in the last quarter. Massachusetts Financial Services Co. MA acquired a new position in shares of DexCom in the 4th quarter valued at $231,773,000. Winslow Capital Management LLC purchased a new stake in DexCom during the third quarter worth $173,120,000. Finally, Vaughan Nelson Investment Management L.P. boosted its holdings in DexCom by 16,943.0% during the third quarter. Vaughan Nelson Investment Management L.P. now owns 1,459,730 shares of the medical device company’s stock worth $136,193,000 after buying an additional 1,451,165 shares in the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Trading Down 2.4 %

Shares of DexCom stock opened at $115.30 on Friday. The company has a debt-to-equity ratio of 1.08, a current ratio of 2.90 and a quick ratio of 2.53. The stock’s 50 day simple moving average is $130.13 and its 200-day simple moving average is $125.61. The stock has a market cap of $45.85 billion, a P/E ratio of 74.39, a P/E/G ratio of 2.85 and a beta of 1.22. DexCom, Inc. has a 1-year low of $74.75 and a 1-year high of $142.00.

DexCom (NASDAQ:DXCMGet Free Report) last released its quarterly earnings data on Thursday, April 25th. The medical device company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. DexCom had a return on equity of 31.01% and a net margin of 16.82%. The company had revenue of $921.00 million for the quarter, compared to analyst estimates of $911.20 million. Analysts predict that DexCom, Inc. will post 1.78 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. UBS Group upped their price objective on shares of DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a research report on Wednesday, April 10th. Canaccord Genuity Group upped their price target on DexCom from $144.00 to $145.00 and gave the stock a “buy” rating in a report on Friday, April 26th. Raymond James raised their price objective on DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a report on Friday, April 26th. Royal Bank of Canada assumed coverage on DexCom in a research note on Tuesday, March 12th. They set an “outperform” rating and a $165.00 target price for the company. Finally, Redburn Atlantic initiated coverage on shares of DexCom in a research note on Thursday, May 30th. They issued a “neutral” rating and a $130.00 price target on the stock. Three research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $140.94.

Get Our Latest Report on DXCM

Insider Activity at DexCom

In other news, EVP Michael Jon Brown sold 629 shares of the stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $126.25, for a total value of $79,411.25. Following the completion of the sale, the executive vice president now owns 68,212 shares of the company’s stock, valued at approximately $8,611,765. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other DexCom news, EVP Sadie Stern sold 20,321 shares of the company’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $133.61, for a total value of $2,715,088.81. Following the transaction, the executive vice president now owns 80,441 shares of the company’s stock, valued at $10,747,722.01. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Michael Jon Brown sold 629 shares of the stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $126.25, for a total transaction of $79,411.25. Following the transaction, the executive vice president now directly owns 68,212 shares of the company’s stock, valued at approximately $8,611,765. The disclosure for this sale can be found here. Over the last quarter, insiders sold 187,293 shares of company stock valued at $25,295,452. 0.30% of the stock is owned by company insiders.

DexCom Profile

(Free Report)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Recommended Stories

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.